 |
4 Diseases |  |
49 Trials |
|
49 Trials |  |
1092 News |  |
| «12...45678910111213141516» |
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: The combo of the anti–LAG-3 agent relatlimab plus the PD-1 agent nivolumab resulted in a superior PFS benefit over nivolumab alone, and the efficacy achieved with the doublet did not come at the cost of increased toxicity @HTawbi_MD @MDAndersonNews #melsm https://t.co/h4o0hmK0RS (Twitter) - Oct 17, 2021
- | relatlimab (BMS-986016) / BMS, Ono Pharma, Opdualag (nivolumab/relatlimab) / BMS, Ono Pharma
New P2 trial, Metastases: A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma (clinicaltrials.gov) - Oct 14, 2021
P2, N=40, Recruiting, Sponsor: California Pacific Medical Center Research Institute
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Review, Combination therapy: #relatlimab anti-LAG3 in combination with #nivolumab (#Opdivo) speeds along regulatory path to approval for #melanoma, now accepted for review by US @FDAOncology and European EMEA https://t.co/sfNeXWBhlg (Twitter) - Oct 13, 2021
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov) - Oct 1, 2021
P1/2, N=107, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jan 2021 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Feb 2022
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Relatlimab/Nivolumab Improves PFS Without Added Toxicity in Metastatic Melanoma, Underscoring Frontline SOC Potential @HTawbi_MD @MDAndersonNews #melsm https://t.co/iEBekKDTk8 (Twitter) - Sep 30, 2021
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Much expected news from @FDAOncology regarding @BMS_ImmunOnc_US regulatory application for #relatlimab in combo with #nivolumab #opdivo for #melanoma https://t.co/Hbkp8KtCq7 (Twitter) - Sep 22, 2021
- | Enrollment open, Trial initiation date: Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (clinicaltrials.gov) - Sep 20, 2021
P1, N=36, Recruiting, Sponsor: Carlo Contreras
Trial completion date: Jan 2021 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Feb 2022 Not yet recruiting --> Recruiting | Initiation date: Feb 2021 --> Nov 2021
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: stage II/ III Melanoma ideally should move on to neoadjuvant Nivo + Relatlimab few doses ( avoid Ipi toxicity) . No further Rx if pCR or MRD- . If stage II found after surgery -> adj Pembro or Nivo x1 yr based on MRD. (Twitter) - Sep 18, 2021
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Certainly figuring how to combine and sequence ipi in the new nivo+relatlimab era will be incredibly important for practice and improving the outcomes of our melanoma patients (Twitter) - Sep 18, 2021
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
The data suggests that it is certainly practice changing and can replace single agent nivolumab! Nivo+ipi still has a major role, including in Brain Mets and other populations where nivo+ipi has significant activity and no data yet for nivo+relatlimab (Twitter) - Sep 18, 2021
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Relatlimab+Nivolumab improves Treatment Free Interval &quite remarkably PFS2 (PFS on subsequent therapy). All without major increase in toxicity over nivo alone (18.9% vs 9.7% gr 3-4 irAEs). Great presentation by Steve Hodi #ESMO21 @ProfGLongMIA @evanlipson Dirk Schadendorf (Twitter) - Sep 18, 2021
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
One could think 6:30 AM on a Saturday in Houston is a bit early for science but quite excited about the upcoming #ESMO21 Melanoma Session, promising for some solid data especially for nivolumab + relatlimab!.. (Twitter) - Sep 18, 2021
- |||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Evan J. Lipson, MD, on Melanoma: Relatlimab and Nivolumab in First-Line Treatment of Advanced Disease https://t.co/m4oVCZln98 #melsm #oncology #immunotherapy @evanlipson (Twitter) - Sep 17, 2021
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment closed: A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab (clinicaltrials.gov) - Sep 16, 2021
P1, N=24, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Feb 2021 --> Nov 2021 Recruiting --> Active, not recruiting
- | Remicade (infliximab) / J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
New P2 trial, Adverse events: PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma (clinicaltrials.gov) - Sep 5, 2021
P2, N=36, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Checkpoint inhibition: Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) - Aug 27, 2021
P2, N=53, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, IO biomarker: RELATIVITY-073: A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors (clinicaltrials.gov) - Aug 18, 2021
P2, N=250, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Jun 2024
- || Empliciti (elotuzumab) / AbbVie, BMS, relatlimab (BMS-986016) / BMS, renvistobart (BMS-986207) / BMS
Trial completion date, Trial primary completion date, Immuno-oncology: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=104, Recruiting, Sponsor: Multiple Myeloma Research Consortium
Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Jun 2024 Trial completion date: Mar 2022 --> Dec 2024 | Trial primary completion date: Mar 2022 --> Dec 2024
- | relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Next up: the RELATIVITY TRIAL led by Dr. Lipson. The combination of relatlimab + nivolumab was better than NIVO alone for progession-free survival at 27 months. (Twitter) - Aug 9, 2021
- ||| nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Enrollment open, Combination therapy, Checkpoint inhibition, Checkpoint block, Metastases, Immuno-oncology: TS-PERIO-01: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma (clinicaltrials.gov) - Aug 8, 2021
P1, N=80, Recruiting, Sponsor: TriSalus Life Sciences, Inc.
Trial completion date: Mar 2022 --> Dec 2024 | Trial primary completion date: Mar 2022 --> Dec 2024 Not yet recruiting --> Recruiting
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs nivo with chemotherapy in stage IV or recurrent non-small cell lung cancer (NSCLC): A phase II, randomized, double-blind study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2643;
P2
Secondary endpoints (part 2) include evaluation of the safety and tolerability of RELA + NIVO + PDCT, PFS across biomarker subgroups, and objective response rate. This global study is now enrolling patients.
- ||| Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: FRACTION-GC: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (clinicaltrials.gov) - Jul 19, 2021
P2, N=186, Active, not recruiting, Sponsor: Bristol-Myers Squibb
This global study is now enrolling patients. Recruiting --> Active, not recruiting | N=600 --> 186 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Nov 2021 --> Apr 2023
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / Ono Pharma, BMS
Biomarker, New P2 trial: ARID1A and/or KDM6A Mutation and CXCL13 Expression (clinicaltrials.gov) - Jul 6, 2021
P2, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma () - Jul 6, 2021 - Abstract #BOABrazil2021BOA_Brazil_14;
- relatlimab (BMS-986016) / BMS, Ono Pharma, nivolumab/relatlimab (BMS-986213) / BMS, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Relatlimab (RELA) + nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase 3 results from RELATIVITY-047 (CA224-047) () - Jul 6, 2021 - Abstract #BOABrazil2021BOA_Brazil_11;
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date: RELATIVITY-104: A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 1, 2021
P2, N=520, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=600 --> 186 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Nov 2021 --> Apr 2023 Trial completion date: Feb 2024 --> Sep 2024
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: From @OncLive - @HTawbi_MD on the Safety Profile of Relatlimab Plus Nivolumab in Advanced #Melanoma https://t.co/WeC6X9rybM (Twitter) - Jun 25, 2021
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Checkpoint inhibition: Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov) - Jun 23, 2021
P1, N=18, Active, not recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Trial completion date: Feb 2024 --> Sep 2024 Trial primary completion date: Jun 2021 --> Jan 2022
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Video: Highlights from #ASCO21 👀 watch @evanlipson presenting primary phase III results from RELATIVITY-047: Relatlimab + Nivolumab vs NIVO in first-line advanced #melanoma ▶️ Full video: https://t.co/Eb587hFT7p #melsm #oncology (Twitter) - Jun 22, 2021
- | nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
New P1 trial, Combination therapy, Checkpoint inhibition, Checkpoint block, Metastases, Immuno-oncology: TS-PERIO-01: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma (clinicaltrials.gov) - Jun 21, 2021
P1, N=80, Not yet recruiting, Sponsor: TriSalus Life Sciences, Inc.
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Neoadjuvant NIVO + RELATLIMAB in resectable #Melanoma ? ⬆️pCR (59%) and MPR (66%) ⬆️ RFS in pts with MPR (no relapses with 16 mo of mFU) ⬇️ Toxicity #ASCO21 #Melanoma 🏖️ (Twitter) - Jun 17, 2021
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma
FDA event: BMS should focus on developing Relatlimab in NSCLC now that FDA approval in melanoma is all but assured after the RELATIVITY data.. (Twitter) - Jun 14, 2021
- ||| Opdivo (nivolumab) / BMS
Enrollment change: REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (clinicaltrials.gov) - Jun 11, 2021
P1/2, N=21, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial primary completion date: Jun 2021 --> Jan 2022 N=30 --> 21
- | relatlimab (BMS-986016) / BMS, Ono Pharma
進行悪性黒色腫に対する1次治療として、抗LAG-3抗体relatlimabとニボルマブの固定用量配合剤（FDC）を用いた併用療法は、ニボルマブ単剤療法と比較して無増悪生存期間（PFS）を有意に延長することが報告されました。 #悪性黒色腫 #relatlimab #ニボルマブ #ASCO21 https://t.co/G0D4m8v6o0 (Twitter) - Jun 10, 2021
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: 3/ Compelling (and first ph3) data validating LAG-3 as 3rd new CPI target in #immunotherapy: in adv melanoma, relatlimab + nivo beats nivo alone. Could be comparable in efficacy to nivo + ipi combo, but less tox #ASCO21 @evanlipson https://t.co/iYRjvMGBLm https://t.co/yJw6GZrlZT (Twitter) - Jun 8, 2021
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: New therapies always exciting (relatlimab!) but also v important to learn how to optimize ipi/nivo for efficacy/tox - ADAPT-IT @MPostow Checkmate-511 @CelesteLebbe (Twitter) - Jun 6, 2021
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: .@HTawbi_MD, PhD, of @MDAndersonNews discusses the efficacy of relatlimab plus nivolumab in patients with advanced melanoma. @ASCO #ASCO21 #melcsm https://t.co/gJbUUMRmdi (Twitter) - Jun 6, 2021
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Poster session by @LutzkyJose @SylvesterCancer- Ph II nivo +relatlimab in pts with Metastatic Uveal Melanoma #melanoma (Twitter) - Jun 6, 2021
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Checkpoint inhibition: First CTLA-4, then PD-1, now LAG-3 as a target for immune checkpoint inhibition.... #asco21 abstract 9503 presented by @evanlipson: RELATIVITY-047 trial of combination of Relatlimab (Anti–LAG-3 Antibody) and Nivolumab in Advanced Melanoma https://t.co/O9C1My8NWe (Twitter) - Jun 6, 2021
- ||||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, P2 data: #ASCO21 Poster Session by @LutzkyJose: NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal #melanoma (UM) (CA224-094). @JWHarbourMD @ASCO (Twitter) - Jun 6, 2021
P2
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Licensing / partnership: Thank you @alexshoushtari @MPostow @DrBetofMDPhD Dr. Charlotte Aryan & rest of the team @sloan_kettering for an incredible collaboration with our @MDAndersonNews team- couldn’t have done the neoadjuvant nivo+relatlimab study without your partnership and support! (Twitter) - Jun 6, 2021
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma
Although questions remain to be answered about OS, Relatlimab is not just the “new kid (drug) on the block”, but likely here to stay as a new combination option for 1L #melanoma. https://t.co/VmxkDULbNI #ASCO21 (Twitter) - Jun 6, 2021
- || relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Agree- great news for relatlimab! Wonder why nivo arm did so poorly in this study though. (Twitter) - Jun 6, 2021
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: #ASCO21 #melsm next up- the highly anticipated RELATIVITY-047 @evanlipson. Nivo +/- relatlimab in first line met #melanoma. Improved PFS (HR 0.75). Tox comparable to nivo alone. Exciting to activity for relatlimab in the metastatic and neoadjuvant settings in the one session! (Twitter) - Jun 6, 2021
- ||| relatlimab (BMS-986016) / BMS, Ono Pharma
Relatlimab, anti LAG 3 not LAGGING behind anymore in #melanoma 👍👏 @HTawbi_MD (Twitter) - Jun 6, 2021
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Take home on nivo + relatlimab (anti-LAG3) in 1L advanced #melanoma: more than double PFS in comparison to nivo (10.1 v 4.6 mo, HR 0.75, p=0.0055) Both drugs mixed in 1 vial - easier for pt and less error OSS, ORR blinded still Toxicity similar Likely new SOC... #ASCO21 (Twitter) - Jun 6, 2021
- |||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Relatlimab and combo PD-1 LAG-3 inhibition having a coming out party in #melanoma oral session #ASCO2021 ... Reduced risk of 1L progression by 25% vs nivo alone and 59% path CR rate in neoadj setting. Congrats, colleagues! (Twitter) - Jun 6, 2021
- || relatlimab (BMS-986016) / BMS, Ono Pharma
Tagged the wrong group of relatlimab investigators! Too many good abstracts 😄 @MPostow @mcquadeMDLAc @GlitzaMDPhD @DrSapnaPatel @JenWargoMD (Twitter) - Jun 6, 2021
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: Relatlimab + Nivo doubles median PFS over nivo alone (HR 0.75, p=0.0055) 1 year PFS 47% similar to 1 year PFS of ipi+nivo with minimal added irAEs (18.9%) which is also much better than ipi+nivo (55%). New standard of care for first line melanoma! #ASCO21 (Twitter) - Jun 6, 2021
- ||||| relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Neoadj nivo+relatlimab (anti-LAG3) showing pCR 59% in the context of pCR in other neoadj studies showing very high rates of subsequent RFS, OS. Notably pathologic response different from radiologic response - Amaria #melanoma #ASCO21 (Twitter) - Jun 6, 2021